Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 2, 2009, Pages 417-423

  Shen, Ying Chun ^a,b   Hu, Fu Chang ^b   Jeng, Yung Ming ^b   Chang, Yu Ting ^c   Lin, Zhong Zhe ^b   Chang, Ming Chu ^c   Hsu, Chiun ^b,c   Cheng, Ann Lii ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; PROTEIN AURORA; PROTEIN P53; REGULATOR PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 85042604266     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0691     Document Type: Article

References (44)

1. de Groen PC, Larusso NF, Gunderson LL, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368-78.
2. Hsu C, Shen YC, Yang CH, et al. Weekly gemcitabine plus 24-hour infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer 2004;90:1715-9.
3. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96: 896-902.
4. Jarnagin WR, Klimstra DS, Hezel M, et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 2006;24:1152-60.
5. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-83.
6. Garber K. Divide and conquer: new generation of drugs targets mitosis. J Natl Cancer Inst 2005;97:874-6.
7. Vagnarelli P, Earnshaw WC. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 2004;113: 211-22.
8. Carmena M, Earnshaw MC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54.
9. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22: 451-64.
10. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 2004;4:927-36.
11. Lin ZZ, Hsu HC, Hsu CH, et al. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma. J Hepatol. In press.
12. Lanni JS, Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol 1998;18: 1055 - 64.
13. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66:7668-77.
14. Washington K, Gottfried MR. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver 1996;16:99-104.
15. Arora DS, Ramsdale J, Lodge JP, et al. p53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases. Histopathology 1999;34:497-501.
16. Jan YY, Yeh TS, Yeh JN, et al. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma. Ann Surg 2004;240:89-94.
17. Khan SA, Thomas HC, Toledano MB, et al. p53 mutations in human cholangiocarcinoma: a review. Liver Int 2005;25:704-16.
18. Chen J, Jin S, Tahir SK, et al. Survivin enhances Aurora-B kinase activity and localizes Aurora-B in human cells. J Biol Chem 2003;278: 486-90.
19. Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 2001;11:49-54.
20. Aaron D. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004;64:7183-90.
21. Fleming ID, Cooper JS, Henson DE, et al. editors. American Joint Committee on Cancer staging manual. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 1997.
22. Avery G. Endogeneity in logistic regression models. Emerg Infect Dis 2005;11:503-4.
23. Tsai TL, Shau WY, Hu FC. Generalized path analysis and generalized simultaneous equations model for recursive systems with responses of mixed types. Struct Equation Modeling 2006;13:229-51.
24. Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320-9.
25. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004;10:2065-71.
26. Gautschi O, Heightway J, Mack PC, et al. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1639-48.
27. Katayama H, Ota T, Jisaki F, et al. Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 1999;91:1160-2.
28. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7: 107-17.
29. Sausville EA. Aurora kinases dawn as cancer drug targets. Nat Med 2004;10:234-5.
30. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005;5: 773-85.
31. Chun AC, Jin DY. Transcriptional regulation of mitotic checkpoint gene MAD1 by p53. J Biol Chem 2003;278:37439-50.
32. Iwanaga Y, Jeang KT. Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant. Cancer Res 2002;62: 2618-24.
33. Gjoerup OV, Wu J, Chandler-Militello D, et al. Surveillance mechanism linking Bub1 loss to the p53 pathway. Proc Natl Acad Sci U S A 2007;104:334-9.
34. Gizatullin F, Yao Y, Kung V, et al. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66:7668-77.
35. Tao Y, Zhang P, Frascogna V, et al. Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br J Cancer 2007;97:1664-72.
36. Tao Y, Zhang P, Girdler F, et al. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 2008;27:3244-55.
37. Tsuno T, Natsume A, Katsumata S, et al. Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells. J Neurooncol 2007;83:249-58.
38. Zohoori N, Savitz DA. Econometric approaches to epidemiologic data: relating endogeneity and unobserved heterogeneity to confounding. Ann Epidemiol 1997;7:251 -7.
39. Kallio MJ, Nieminen M, Eriksson JE. Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J 2001;15:2721-3.
40. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4:592-603.
41. Li F, Altieri DC. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999;59:3143-51.
42. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. Survivin is required for stable checkpoint activation in Taxol-treated HeLa cells. J Cell Sci 2003;116:2987-98.
43. Honda R, Korner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, survivin in mitosis. Mol Biol Cell 2003; 14:3325-41.
44. Javle MM, Tan D, Yu J, et al. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology 2004; 51:1653-7.